The below Parliamentary question was asked by Tessa Munt on 2014-06-04.
To ask the Secretary of State for Health, with reference to the Answer of 24 March 2014, Official Report, column 132W, on radiotherapy, and with reference to section 3 of the guidance issued by Monitor on the Commissioning of Radiosurgery Services on 4 April 2014, for what reasons NHS England is not funding patients to be treated with the gamma knife at University College Hospital London.
Jane Ellison
Section 3 of Monitor’s substantive guidance on The National Health Service (Procurement, Patient Choice and Competition) (No.2) Regulations 2013 provides guidance to commissioners on publishing new contract opportunities for National Health Service health care services.
On page 42 of the guidance, it states that "a commissioner may decide to carry out a detailed review of the provision of particular services (for example, A&E services) in its local area in order to understand how those services can be improved in the interests of patients. The review may involve extensive public consultation and engagement with existing and potential providers and other stakeholders. Reviewing available services and providers in this way is good commissioning practice and something that commissioners should consider doing as a matter of course."
In its role as commissioner, NHS England is currently undertaking such a review of stereotactic radiosurgery services. This will inform procurement decisions for these services.
University College London Hospitals is not contracted by NHS England, nor was it contracted by former primary care trusts, to provide Gamma Knife services. It is for this reason that NHS patients cannot normally be treated at this facility. Instead, NHS patients requiring Gamma Knife treatment should be treated by the Gamma Knife services commissioned by the NHS, that have been shown to meet NHS England service specifications. These can be accessed by patients in London without a waiting time, fully maintaining the continuity of their care and normally with the same consultant and clinical team.
Until the capacity requirements are made clear as part of the review being undertaken, NHS England has said that it would be inappropriate to encourage new market entrants to provide this service as it cannot be clear what the potential consequential impacts on service quality, sustainability (financial and clinical) and potential unintended changes to patient pathways will be. Until the review is complete NHS England has said no substantive changes will be made to the current provision.
